Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004763|
Recruitment Status : Completed
First Posted : February 25, 2000
Last Update Posted : June 24, 2005
I. Evaluate the beneficial effects of leuprolide depot, oral contraceptive therapy, and leuprolide/oral contraceptive therapy in the management of patients with ovarian hyperandrogenism.
|Condition or disease||Intervention/treatment||Phase|
|Hyperandrogenism||Drug: leuprolide Drug: Ethinyl estradiol/norethindrone||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||45 participants|
|Study Start Date :||January 1993|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004763
|Study Chair:||Karen E. Elkind-Hirsch||Baylor College of Medicine|